Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.

Organophosphorus pesticides (OPs) remain a potential concern to human health because of their continuing use worldwide. Phosphororthioate OPs like chlorpyrifos and parathion are directly activated and detoxified by various cytochrome P450s (CYPs), with the primary CYPs involved being CYP2B6 and CYP2C19. The goal of the current study was to convert a previously reported human pharmacokinetic and pharmacodynamic (PBPK/PD) model for chlorpyrifos, that used chlorpyrifos metabolism parameters from rat liver, into a human CYP based/age-specific model using recombinant human CYP kinetic parameters (V(max), K(m)), hepatic CYP content and plasma binding measurements to estimate new values for acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibition and to use the model as a template for the development of a comparable parathion PBPK/PD model. The human CYP based/age-specific PBPK/PD models were used to simulate single oral exposures of adults (19 year old) and infants (1 year) to chlorpyrifos (10,000, 1000 and 100 μg/kg) or parathion (100, 25 and 5 μg/kg). Model simulations showed that there is an age dependency in the amount of blood cholinesterase inhibition observed, however additional age-dependent data are needed to further optimize age-specific human PBPK/PD modeling for these OP compounds. PBPK/PD model simulations estimated that a 4-fold increase or decrease in relative CYP2B6 and CYP2C19 content would produce a 9-22% inhibition in blood AChE activity following exposure of an adult to chlorpyrifos (1000 μg/kg). Similar model simulation produced an 18-22% inhibition in blood AChE activity following exposure of an adult to parathion (25 μg/kg). Individuals with greater CYP2B6 content and lower CYP2C19 content were predicted to be most sensitive to both OPs. Changes in hepatic CYP2B6 and CYP2C19 content had more of an influence on cholinesterase inhibition for exposures to chlorpyrifos than parathion, which agrees with previously reported literature that these CYPs are more reaction biased for desulfurization (activation) and dearylation (detoxification) of chlorpyrifos compared to parathion. The data presented here illustrate how PBPK/PD models with human enzyme-specific parameters can assist ongoing risk assessment efforts and aid in the identification of sensitive individuals and populations.

[1]  B. Alexander,et al.  Chlorpyrifos exposure in farm families: Results from the farm family exposure study , 2006, Journal of Exposure Science and Environmental Epidemiology.

[2]  Charles Timchalk,et al.  An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  J. Chambers,et al.  Age-related differences in parathion and chlorpyrifos toxicity in male rats: target and nontarget esterase sensitivity and cytochrome P450-mediated metabolism. , 1997, Toxicology and applied pharmacology.

[4]  K. Jamil,et al.  Human serum paraoxonase gene polymorphisms and association with chronic symptoms of pesticide toxicity in Indian farmers , 2009 .

[5]  S. Imaoka,et al.  A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. , 1997, Life sciences.

[6]  Dana B Barr,et al.  Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat. , 2009, Toxicology.

[7]  J. Stevens,et al.  Human hepatic CYP2B6 developmental expression: the impact of age and genotype. , 2009, Biochemical pharmacology.

[8]  M. Hooper,et al.  Maturational differences in chlorpyrifos-oxonase activity may contribute to age-related sensitivity to chlorpyrifos. , 1996, Journal of biochemical toxicology.

[9]  Z. Radić,et al.  Differentiation of esterases reacting with organophosphorus compounds. , 1993, Chemico-biological interactions.

[10]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[11]  J. Chambers,et al.  Kinetic parameters of desulfuration and dearylation of parathion and chlorpyrifos by rat liver microsomes. , 1994, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[12]  D. Barr,et al.  Concentrations of selective metabolites of organophosphorus pesticides in the United States population. , 2005, Environmental research.

[13]  E. Testai,et al.  CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. , 2003, Toxicology and applied pharmacology.

[14]  G. Tucker,et al.  Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. , 2003, British journal of clinical pharmacology.

[15]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[16]  D. Herndon,et al.  Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications. , 2001, The Journal of trauma.

[17]  B. Ring,et al.  Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.

[18]  A. Samii,et al.  Human PON1, a biomarker of risk of disease and exposure. , 2010, Chemico-biological interactions.

[19]  D. Greenblatt,et al.  CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[20]  C Timchalk,et al.  A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  R. A. Neal.  Studies on the metabolism of diethyl 4-nitrophenyl phosphorothionate (parathion) in vitro. , 1967, The Biochemical journal.

[22]  M Sue Marty,et al.  The effect of plasma lipids on the pharmacokinetics of chlorpyrifos and the impact on interpretation of blood biomonitoring data. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  A. Usmani,et al.  Pesticide metabolism in humans, including polymorphisms. , 2005, Scandinavian journal of work, environment & health.

[24]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[25]  Charles Timchalk,et al.  Comparative inter-species pharmacokinetics of phenoxyacetic acid herbicides and related organic acids. evidence that the dog is not a relevant species for evaluation of human health risk. , 2004, Toxicology.

[26]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[27]  A. Tward,et al.  Expression of human paraoxonase (PON1) during development. , 2003, Pharmacogenetics.

[28]  Ronald N. Hines,et al.  Developmental Expression of the Major Human Hepatic CYP3A Enzymes , 2003, Journal of Pharmacology and Experimental Therapeutics.

[29]  C Timchalk,et al.  Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model. , 2002, Toxicology letters.

[30]  M. Schwab,et al.  Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. , 2007, Pharmacogenomics.

[31]  M. Bartels,et al.  The effect of route, vehicle, and divided doses on the pharmacokinetics of chlorpyrifos and its metabolite trichloropyridinol in neonatal Sprague-Dawley rats. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[32]  C. Dary,et al.  Physicochemical and Biological Data for the Development of Predictive Organophosphorus Pesticide QSARs and PBPK/PD Models for Human Risk Assessment , 2004, Critical reviews in toxicology.

[33]  S. D. Murphy,et al.  Kinetic analyses of the microsomal biotransformation of the phosphorothioate insecticides chlorpyrifos and parathion. , 1983, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[34]  Sean M Hays,et al.  Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy , 2009, Journal of Exposure Science and Environmental Epidemiology.

[35]  A. Povey.  Gene-environmental interactions and organophosphate toxicity. , 2010, Toxicology.

[36]  P. Kostyniak,et al.  Human Hepatic Cytochrome P450-Specific Metabolism of Parathion and Chlorpyrifos , 2007, Drug Metabolism and Disposition.

[37]  R. Fenske,et al.  Biomarkers of Chlorpyrifos Exposure and Effect in Egyptian Cotton Field Workers , 2011, Environmental health perspectives.

[38]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[39]  C. Vidair.  Age dependence of organophosphate and carbamate neurotoxicity in the postnatal rat: extrapolation to the human. , 2004, Toxicology and applied pharmacology.

[40]  J. Albers,et al.  Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers , 2010, Journal of Exposure Science and Environmental Epidemiology.

[41]  M. Moran,et al.  Sensitive method for the determination of organophosphorus pesticides in fruits and surface waters by high-performance liquid chromatography with ultraviolet detection , 1992 .

[42]  Kannan Krishnan,et al.  CHARACTERIZATION OF AGE-RELATED CHANGES IN BODY WEIGHT AND ORGAN WEIGHTS FROM BIRTH TO ADOLESCENCE IN HUMANS , 2001, Journal of toxicology and environmental health. Part A.

[43]  J W Fisher,et al.  In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.

[44]  S. Ekins,et al.  Further characterization of the expression in liver and catalytic activity of CYP2B6. , 1998, The Journal of pharmacology and experimental therapeutics.

[45]  A. Tward,et al.  Paraoxonase 1 (PON1) status and risk of insecticide exposure , 2005, Journal of biochemical and molecular toxicology.

[46]  T. Parrón,et al.  Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure , 2003, Human & experimental toxicology.

[47]  L G Sultatos,et al.  Mammalian toxicology of organophosphorus pesticides. , 1994, Journal of toxicology and environmental health.

[48]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[49]  C. Pope,et al.  Carboxylesterase and A-esterase activities during maturation and aging: relationship to the toxicity of chlorpyrifos and parathion in rats. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  Richard A Fenske,et al.  Chlorpyrifos exposures in Egyptian cotton field workers. , 2010, Neurotoxicology.

[51]  A. Rettie,et al.  Developmental Expression of Human Hepatic CYP2C9 and CYP2C19 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[52]  D. Stresser,et al.  Monospecific antipeptide antibody to cytochrome P-450 2B6. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[53]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[54]  J. Lipscomb,et al.  Covariation of Human Microsomal Protein Per Gram of Liver with Age: Absence of Influence of Operator and Sample Storage May Justify Interlaboratory Data Pooling , 2008, Drug Metabolism and Disposition.

[55]  Jordan N. Smith,et al.  Effect of in vivo nicotine exposure on chlorpyrifos pharmacokinetics and pharmacodynamics in rats. , 2010, Chemico-biological interactions.

[56]  N. Božina,et al.  Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk , 2009, Arhiv za higijenu rada i toksikologiju.

[57]  F. Guengerich,et al.  Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver. , 2000, Archives of biochemistry and biophysics.

[58]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[59]  J. Deddens,et al.  Determinants of chlorpyrifos exposures and urinary 3,5,6-trichloro-2-pyridinol levels among termiticide applicators. , 2001, The Annals of occupational hygiene.